Google Antigravity enhances drug discovery with cheminformatics skills

Google DeepMind's agent platform links more than 30 scientific databases to compress research workflows from days into minutes Google DeepMind wants AI agents to do more than write code and summarize emails. Its Antigravity platform is now being pointed at drug discovery, where a single bad lead can burn months of lab time. In an October 15, 2026 technical demonstration, the platform helped identify a new antimicrobial peptide candidate. From millions of entries to one candidate The demo centered on antimicrobial peptides, short chains of amino acids that can fight bacteria. Researchers used DeepMind’s ProtNLM model to sift through millions of unannotated UniProt entries. UniProt is a large public protein database. “Unannotated” means many of those entries have no known function attached. Out of that pile, the workflow surfaced a new peptide candidate. It shows promising activity against respiratory pathogens, specifically Streptococcus pseudopneumoniae. The candidate was then checked in silico using AlphaFold, DeepMind’s protein structure prediction model. In silico simply means the testing happened on a computer rather than in a petri dish. The process ended with a wet-lab experi...